

Brain+ A/S intends to add three international life science profiles as new board members in a strategic move ahead of its near-term commercial launch

Monday, August 8, 2022, 8:30 CET

The Board of Directors of Brain+ A/S ("Brain+") hereby notifies of its intention to convene an Extraordinary General Meeting ("EGM") on Friday, September 2, 2022. The purpose of the EGM is the election of three new board members, nominated as candidates by the Board of Directors: Anders Härfstrand, Chairman of Diurnal Group, Johan Luthman, EVP & Head of R&D at Lundbeck, and Betül Susamis Unaran, Member of the Board of Directors of Ypsomed. The candidates represent a valuable span of international competencies of high relevance for Brain+'s near-term move into commercialization and subsequent business expansion.

The strategic partnership with RoX Health, a part of Roche, is advancing successfully. Based on the valuable insights and support from the partnership, Brain+ confirms its plans for the commercial launch of its first digital therapeutic dementia product in Denmark and Germany already in 2023, two years ahead of expectations at the time of the Company's IPO in October 2021.

With the accelerated launch prospects, Brain+ is about to enter a new commercialization phase. To support this evolution, the board is very pleased to nominate three strong industry candidates with significant international experience and competencies in Digital Therapeutics marketing, Life Science business development, clinical development, and regulatory procedures.

Anders Härfstrand is Chairman at Diurnal Group and former Executive Vice President at Pfizer Pharmaceuticals. He brings extensive experience in global business development and new product commercialization as chief executive at multiple pharmaceutical companies.

Johan Luthman is Executive Vice President and Head of R&D at Lundbeck, with great experience within dementia and neuroscience also from his former position as Senior Program Leader of Neuroscience R&D at Merck, and as CEO of GoNeuro.

Betül Susamis Unaran is on the Board of Directors of Ypsomed, and brings extensive Digital Therapeutics and Pharma experience as Chief Strategy and Digital Officer at the largest e-commerce pharmacy in Europe, Zur Rose Group and as member of their executive board, and formerly as Global Head of Digital Medicines at Novartis Pharmaceuticals.

"I am truly pleased that Brain+ has been able to attract such experienced and talented new board nominees. Johan's deep expertise in dementia and Alzheimer's will be invaluable for our clinical development. Betül is a star within Pharma and Digital Therapeutics, and Anders, an M.D. and PhD in neuroendocrinology from the Karolinska Institutet, is one of the most experienced Life Science board members in Europe" says Chairman Lars Terney, private investor and Senior partner, Nordic Capital.

In connection with the Extraordinary General Meeting, Jonas Nilsen has announced his intention to retire from the board to make room for the new additions.

"On behalf of the Board, I would like to thank Jonas for his contributions to Brain+. He has played a vital role in the development of the company for the last couple of years," says Chairman Lars Terney.

Contact Information

CEO and Co-founder: Kim Baden-Kristensen, + 45 31393317, kim@brain-plus.com
Certified Advisor: Keswick Global AG, + 43 1740408045, info@keswickglobal.com